查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
過度活躍的膀胱治療(OAB)市場：按類型(抗膽鹼能藥物、肉毒桿菌毒素、神經調節)、疾病類型(特發性 OAB、神經性 OAB)、地區世界預測至2027
市場調查報告書
商品編碼
1099211

過度活躍的膀胱治療(OAB)市場：按類型(抗膽鹼能藥物、肉毒桿菌毒素、神經調節)、疾病類型(特發性 OAB、神經性 OAB)、地區世界預測至2027

Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027
出版日期: | 出版商: MarketsandMarkets | 英文 203 Pages | 訂單完成後即時交付

價格
簡介目錄

全球膀胱過度活動症治療市場預計將從 2022 年的 35 億美元增長到 2027 年的 42 億美元，預測期內的複合年增長率為 3.6%。

全球膀胱過度活動症患病率的增加以及對可用治療方案的認識不斷提高正在推動市場增長。此外，預計在OAB治療中使用神經調節技術會產生更大的積極作用。

“2021 年膀胱過度活動症(OAB)治療市場由 Mirabeglon 細分市場主導”

膀胱過度活動症治療市場按類型分為抗膽鹼能藥物、米拉貝隆、肉毒桿菌毒素、神經調節和其他治療。與市場上可用的其他藥物類別相比，米拉貝隆將在 2021 年佔據壓倒性的市場份額，因為其與該藥物相關的副作用更少。此外，隨著為 OAB 引入新的 SNM 和 PTNS，預計神經分割空間將以更快的速度增長。

“特發性膀胱過度活動症將在預測區間內實現膀胱過度活動症藥物市場的最高增長”

膀胱過度活動症治療市場根據疾病類型分為特發性膀胱過度活動症和神經源性膀胱過度活動症。由於特發性膀胱過度活動症的高發病率和治療藥物的使用增加，特發性膀胱過度活動症佔據了更大的市場份額。

“2021年北美將佔據壓倒性份額”

膀胱過度活動症 (OAB) 治療市場在地理上分為北美、歐洲、亞太地區、拉丁美洲和中東/非洲。到 2021 年，北美將在 OAB 治療市場佔有主要份額。北美擁有導致該地區 OAB 治療市場成熟的大部分主要市場參與者。此外，美國有利的贖回政策是北美市場增長的主要預測因素之一。

本報告中進行的主要訪談分類如下

  • 按公司類型：供應方：80.0%，需求方：20.0%
  • 按職稱：經理：45.0%，CXO 和董事：30.0%，高管：25.0%
  • 按地區劃分：北美：55%，歐洲：20%，亞太地區：10%，拉丁美洲：10%，中東和非洲：5%

本報告中公佈的公司簡介列表

    • Astellas Pharma Inc. (Japan)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Pfizer Inc. (US)
    • Abbvie Inc. (US)
    • Viatris Inc. (US)
    • Hisamitsu Pharmaceutical Co., Inc. (Japan)
    • Johnson & Johnson Services, Inc. (US)
    • Endo Pharmaceuticals Inc. (Ireland)
    • Lupin (India)
    • Amneal Pharmaceuticals Llc (US)
    • Sun Pharmaceutical Industries Ltd. (India)
    • Glenmark (India)
    • Macleods Pharmaceuticals Ltd (India)
    • Medtronic (Ireland)
    • Ajanta Pharma (India)
    • Granules India Limited (India)
    • Urovant Sciences (US)
    • Apotex Inc. (Canada)
    • Laborie (US)
    • Intas Pharmaceuticals Ltd. (India)
    • Bayer Ag (Germany)
    • Medytox (South Korea)
    • Altherx Pharmaceuticals (US)
    • Taiho Pharmaceutical Co., Ltd. (Japan)
    • Hugel, Inc. (South Korea)

調查目標

本報告詳細介紹了全球膀胱過度活動症治療市場。它旨在估計類型、疾病類型和地區等不同細分市場的市場規模和未來增長潛力。我們還分析了影響市場增長的因素(促進因素、市場製約因素、機會等)。它評估利益相關者的市場機會，並為市場領導者提供競爭格局的詳細資訊。我們還在調查細胞分析市場對整個微型市場的增長趨勢、前景和貢獻。該報告預測了四個關鍵地區的細分市場收入。

購買報告的原因

本報告提供以下幾點見解

  • 市場滲透。細胞分析市場中 25 家頂級公司提供的有關細胞分析的綜合信息。這是一份按類型、疾病類型和地區分析膀胱過度活動症治療市場的報告。
  • 新興市場市場。有關有利新興市場的綜合信息。我們正在按主要地區分析各種細胞分析的市場。
  • 市場多元化。有關新產品、未開發領域、膀胱過度活動症 (OAB) 治療市場的最新發展和投資的綜合信息。
  • 競爭評估。詳細評估主要公司在膀胱過度活動症治療市場的市場排名和策略。

目錄

第 1 章介紹

  • 研究目的
  • 市場定義
    • 包含與排除
  • 市場範圍
    • 目標市場
    • 考慮的年份
  • 貨幣
  • 限制
  • 利益相關者
  • 變更摘要

第 2 章調查方法

  • 調查方法
    • 初步調查
    • 自上而下和自下而上的方法
  • 數據三角法
    • 二次調查
    • COVID-19 特定假設
  • 調查限制
  • 風險評估
  • 增長率假設/增長預測
    • 供給側
    • 需求方
      • 來自主要專家的見解

第 3 章執行摘要

第 4 章重要考慮

  • 膀胱過度活躍症市場概況
  • 亞太地區：按類型和國家/地區分列的膀胱過度活動症治療市場份額(2021 年)
  • 2022 年與 2027 年按疾病類型分列的膀胱過度活動症治療市場份額
  • 過度活躍的膀胱治療市場：地理增長機會的機會

第 5 章市場概述

  • 簡介
  • 市場動態
    • 市場促進因素
      • 膀胱過度活動症的患病率增加
      • 人口迅速老齡化，隨後以 OAB 為特徵的疾病發病率增加
      • 創新膀胱內療法的開發和使用
      • 未來幾年不斷增加的研發投資和新療法的推出
    • 市場抑制因素
      • 頻繁的產品召回
      • 抗膽鹼能藥物的副作用增加
    • 市場機會
      • 針對特定藥物的新療法、強大的管道和專利懸崖
    • 市場挑戰
      • 社會污名和缺乏對 OAB 的認識
  • 不確定性對膀胱過度活動症治療市場的影響
  • COVID-19 對膀胱過度活動症治療市場的影響
  • 影響客戶業務的趨勢/動盪
  • 價值鏈分析
  • 供應鏈分析
  • 生態系統分析
  • 監管場景
    • 醫藥行業
      • 監管要求
        • 歐盟法規
        • 美國法規
    • 醫療器械行業
      • 監管要求
        • 歐盟法規
        • 美國法規
  • 技術分析
  • 2022-2023年主要會議和活動
  • 專利分析
  • 波特五力分析
    • 來自新進入者的威脅
    • 來自替代品的威脅
    • 買方的議價能力
    • 供應商的議價能力
    • 競技比賽
  • 價格分析
  • 主要利益相關者和採購標準
  • 管道分析

第 6 章過度活躍的膀胱治療市場：按類型

  • 簡介
  • 米拉貝格隆
    • 與抗膽鹼能藥物相比，副作用更少可能推動該細分市場的增長
  • 抗膽鹼藥
    • 索利那新
      • Solifenacin 在減少尿失禁頻率方面比其他抗膽鹼能藥物更有效——這是推動市場增長的關鍵因素
    • 奧昔布寧
      • Oxybutynin 是 OAB 市場上處方最廣泛的抗膽鹼能藥物。
    • 非索羅定
      • 非索羅定對逼尿肌中的毒蕈鹼乙□膽鹼受體具有抗毒蕈鹼作用，導致膀胱收縮減少。
    • 達非那新
      • Darifenacin 成本高於其他抗膽鹼能藥物，可能在一定程度上減緩市場增長
    • 托特羅定
      • 托特羅定是OAB中的第三種處方藥，因為它副作用少且具有長期的臨床益處。
    • Trospium
      • Trospium 與口乾的發生率低有關，因此停藥率相對較低。
    • 其他抗膽鹼能藥物
  • 肉毒桿菌
    • 肉毒桿菌毒素比抗膽鹼能藥物更有效，使其成為一種流行的治療選擇
  • 神經修飾
    • 越來越多地採用神經調節來治療膀胱過度活動症，以促進該細分市場的增長
  • 其他治療

第 7 章過度活躍的膀胱治療市場：按疾病類型

  • 簡介
  • 特發性膀胱過度活動症
    • 可報銷用於治療特發性 OAB 的藥物以促進該市場的增長
  • 神經性膀胱過度活動症綜合徵
    • 帕金森病
      • 增加使用抗膽鹼能和β-腎上腺素能激動劑治療帕金森病以促進市場增長
    • 中風
      • 腦卒中患病率增加，OAB 發病率增加，OAB 治療需求增加
    • 多發性硬化症
      • 優惠的報銷政策支持 MS 的 OAB 治療市場的增長
    • 脊髓損傷
      • SCI 中膀胱過度活動症的高患病率促進了神經源性膀胱過度活動症治療市場的增長
    • 其他障礙

第 8 章過度活躍的膀胱治療市場：按地區劃分

  • 簡介
  • 北美
    • 美國
      • 優惠的報銷政策使美國成為膀胱多動症治療的最大市場
    • 加拿大
      • BOTOX 治療膀胱過度活動症並推動加拿大市場增長的使用和需求增加
  • 歐洲
    • 德國
      • 老齡化和 OAB 的高患病率，尤其是女性，預計將增加德國的目標患者群體。
    • 英國
      • 在英國開展的旨在推動 OAB 市場增長的舉措和宣傳活動
    • 法國
      • 與其他國家相比，法國的低還款率可能會在一定程度上限制市場增長
    • 意大利
      • 意大利製藥業有望為 OAB 製藥公司提供有利的增長機會。
    • 西班牙
      • 西班牙的人口結構變化和 OAB 的高患病率為膀胱過度活動症治療市場提供了重要的增長機會
    • 其他歐洲
  • 亞太地區
    • 日本
      • 治療方案的進步推動日本市場的增長
    • 中國
      • 越來越多地採用 BOTOX 治療 OAB 使中國成為一個利潤豐厚的市場
    • 印度
      • 印度是全球最大的仿製藥生產國，是推動市場增長的重要因素。
    • 澳大利亞
      • 老齡化人口的增加可能會增加澳大利亞 OAB 患者的數量——這是支持該市場增長的關鍵因素
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
      • 在國內增加使用膀胱過度活動症藥物以促進市場增長
    • 墨西哥
      • 提高 OAB 的滲透率以推動墨西哥市場的增長
    • 其他拉丁美洲
  • 中東和非洲
    • 提高中東地區的知名度可能會推動中東和非洲市場的增長

第 9 章競爭態勢

  • 簡介
  • 關鍵球員採用的獲勝方法
  • 市場份額分析
  • 收入分析
  • 公司評價象限
    • 星星
    • 新興領導者
    • 無所不在的播放器
    • 參與者
  • 前 20 名玩家的競爭基準測試
    • 公司足跡(20 家公司)
    • 公司產品足跡(20 家公司)
    • 公司的區域足跡(20 家公司)
  • 公司評價象限：初創公司/中小企業
    • 進步公司
    • 起始塊
    • 響應式公司
    • 充滿活力的公司
    • 競爭基準/SME Player 競爭基準
  • 競爭場景和趨勢
    • 產品發布和批准
    • 交易

第 10 章公司簡介

  • KEY PLAYERS
    • ASTELLAS PHARMA INC.
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • PFIZER INC.
    • ABBVIE INC.
    • VIATRIS INC.
    • HISAMITSU PHARMACEUTICAL CO., INC.
    • JOHNSON & JOHNSON SERVICES, INC.
    • ENDO PHARMACEUTICALS INC.
    • LUPIN
    • AMNEAL PHARMACEUTICALS LLC
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
    • GLENMARK
    • MACLEODS PHARMACEUTICALS LTD.
    • MEDTRONIC
    • AJANTA PHARMA
    • GRANULES INDIA LIMITED
  • OTHER PLAYERS
    • UROVANT SCIENCES
    • APOTEX INC.
    • LABORIE
    • INTAS PHARMACEUTICALS LTD.
    • BAYER AG
    • MEDYTOX
    • ALTHERX PHARMACEUTICALS
    • TAIHO PHARMACEUTICAL CO., LTD.
    • HUGEL, INC.

第 11 章附錄

簡介目錄
Product Code: PH 5449

The global overactive bladder treatment market is projected to reach USD 4.2 billion by 2027 from USD 3.5 billion in 2022, at a CAGR of 3.6% during the forecast period. Rising prevalence of overactive bladder across the globe coupled with rising awareness about treatment options available is driving the growth of the market. Additionally, use of neuromodulation techniques for the treatment of OAB is further expected to have significant positive impact.

"Mirabergon segment dominates the overactive bladder (OAB) treatment market in 2021."

Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing to the lesser side-effects associated with this drug compared to other drug classes available in the market. Furthermore, neuromodulation segment is expected to grow at faster pace owing to launch of new SNM & PTNS for OAB in market.

"The idiopathic overactive bladder segment will witness the highest growth in overactive bladder treatment market during the forecast period."

Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for the treatment.

"North America held dominant share in 2021."

Geographically, the overactive bladder (OAB) treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share in the OAB treatment market. North America holds majority of the key market players leading to maturity of OAB treatment market in this region. Furthermore, favorable reimbursement policies in US is one of the leading factor projecting market growth in North America.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Supply Side: 80.0%, Demand Side: 20.0%
  • By Designation - Managers: 45.0%, CXOs & Directors:30.0%, Excecutives:25.0%
  • By Region - North America: 55%, Europe: 20%, Asia Pacific: 10%, Latin America: 10%, and the Middle East and Africa: 5%

List of Companies Profiled in the Report

    • Astellas Pharma Inc. (Japan)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Pfizer Inc. (US)
    • Abbvie Inc. (US)
    • Viatris Inc. (US)
    • Hisamitsu Pharmaceutical Co., Inc. (Japan)
    • Johnson & Johnson Services, Inc. (US)
    • Endo Pharmaceuticals Inc. (Ireland)
    • Lupin (India)
    • Amneal Pharmaceuticals Llc (US)
    • Sun Pharmaceutical Industries Ltd. (India)
    • Glenmark (India)
    • Macleods Pharmaceuticals Ltd (India)
    • Medtronic (Ireland)
    • Ajanta Pharma (India)
    • Granules India Limited (India)
    • Urovant Sciences (US)
    • Apotex Inc. (Canada)
    • Laborie (US)
    • Intas Pharmaceuticals Ltd. (India)
    • Bayer Ag (Germany)
    • Medytox (South Korea)
    • Altherx Pharmaceuticals (US)
    • Taiho Pharmaceutical Co., Ltd. (Japan)
    • Hugel, Inc. (South Korea)

Research Coverage:

This report provides a detailed picture of the global overactive bladder treatment market. It aims at estimating the size and future growth potential of the market across different segments, such as type, disease type and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total cell analysis market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on cell analysis offered by the top 25 players in the cell analysis market. The report analyses the overactive bladder treatment market by type, disease type and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various cell analysis across key geographic regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the overactive bladder (OAB) treatment market.
  • Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the overactive bladder treatment market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 PRIMARY RESEARCH
    • FIGURE 2 OVERACTIVE BLADDER TREATMENT MARKET: PRIMARY RESPONDENTS
    • 2.1.2 TOP-DOWN AND BOTTOM-UP APPROACHES
    • FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION
  • 2.2 DATA TRIANGULATION APPROACH
    • FIGURE 5 DATA TRIANGULATION METHODOLOGY
    • 2.2.1 SECONDARY RESEARCH
    • 2.2.2 COVID-19-SPECIFIC ASSUMPTIONS
  • 2.3 RESEARCH LIMITATIONS
  • 2.4 RISK ASSESSMENT
  • 2.5 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • 2.5.1 SUPPLY SIDE
    • 2.5.2 DEMAND SIDE
      • 2.5.2.1 Insights from primary experts

3 EXECUTIVE SUMMARY

    • FIGURE 6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE 2022 VS. 2027 (USD MILLION)
    • FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE OVERACTIVE BLADDER TREATMENT MARKET

4 PREMIUM INSIGHTS

  • 4.1 OVERACTIVE BLADDER TREATMENT MARKET OVERVIEW
    • FIGURE 9 RISING PREVALENCE OF OVERACTIVE BLADDER SYNDROME AND FAVORABLE REIMBURSEMENT POLICIES ARE KEY FACTORS DRIVING MARKET GROWTH
  • 4.2 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY TYPE AND COUNTRY (2021)
    • FIGURE 10 MIRABEGRON ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021
  • 4.3 OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY DISEASE TYPE, 2022 VS. 2027
    • FIGURE 11 IDIOPATHIC OVERACTIVE BLADDER SYNDROME SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2027
  • 4.4 OVERACTIVE BLADDER TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 12 US TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 13 OVERACTIVE BLADDER TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 1 OVERACTIVE BLADDER TREATMENT MARKET: IMPACT ANALYSIS
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Rising prevalence of overactive bladder syndrome
      • 5.2.1.2 Rapidly aging population and subsequent rise in incidence of diseases characterized by OAB
    • FIGURE 14 PROJECTED GROWTH IN THE ELDERLY POPULATION ABOVE 60, 2015 VS. 2030 VS. 2050
      • 5.2.1.3 Development and use of innovative intravesical therapies
      • 5.2.1.4 Growing R&D investments and the launch of novel therapies in the coming years
    • 5.2.2 MARKET RESTRAINTS
      • 5.2.2.1 Frequent product recalls
      • 5.2.2.2 Increased side effects of anticholinergic drugs
    • 5.2.3 MARKET OPPORTUNITIES
      • 5.2.3.1 Novel treatments, robust pipelines, and patent cliff of certain drugs
    • 5.2.4 MARKET CHALLENGES
      • 5.2.4.1 Social stigma and lack of awareness about OAB
  • 5.3 IMPACT OF UNCERTAINTIES ON THE OVERACTIVE BLADDER TREATMENT MARKET
    • FIGURE 15 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE OVERACTIVE BLADDER TREATMENT MARKET
  • 5.4 IMPACT OF COVID-19 ON THE OVERACTIVE BLADDER TREATMENT MARKET
  • 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 16 REVENUE SHIFT AND NEW POCKETS FOR THE OVERACTIVE BLADDER TREATMENT MARKET
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 17 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
  • 5.7 SUPPLY CHAIN ANALYSIS
    • FIGURE 18 DIRECT DISTRIBUTION-THE PREFERRED STRATEGY OF PROMINENT COMPANIES
  • 5.8 ECOSYSTEM ANALYSIS
    • FIGURE 19 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY
    • FIGURE 20 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES INDUSTRY
  • 5.9 REGULATORY SCENARIO
    • 5.9.1 PHARMACEUTICAL INDUSTRY
      • 5.9.1.1 Regulatory requirements
        • 5.9.1.1.1 EU regulations
        • 5.9.1.1.2 US regulations
    • 5.9.2 MEDICAL DEVICE INDUSTRY
      • 5.9.2.1 Regulatory requirements
        • 5.9.2.1.1 EU regulations
        • 5.9.2.1.2 US regulations
    • TABLE 2 LIST OF REGULATORY AUTHORITIES
  • 5.10 TECHNOLOGY ANALYSIS
  • 5.11 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 3 OVERACTIVE BLADDER TREATMENT MARKET: LIST OF CONFERENCES AND EVENTS
  • 5.12 PATENT ANALYSIS
    • FIGURE 21 LIST OF MAJOR PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
    • TABLE 4 OVERVIEW OF PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 OVERACTIVE BLADDER TREATMENT MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.13.1 THREAT FROM NEW ENTRANTS
    • 5.13.2 THREAT FROM SUBSTITUTES
    • 5.13.3 BARGAINING POWER OF BUYERS
    • 5.13.4 BARGAINING POWER OF SUPPLIERS
    • 5.13.5 DEGREE OF COMPETITION
  • 5.14 PRICING ANALYSIS
    • TABLE 6 COST OF DRUGS USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS (GENERICS)
    • TABLE 7 COST OF BOTOX AND NEUROMODULATION USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS
    • TABLE 8 COST OF BRANDED DRUGS USED IN OVERACTIVE BLADDER TREATMENT IN VARIOUS REGIONS
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • FIGURE 22 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON THE BUYING PROCESS
    • FIGURE 23 KEY BUYING CRITERIA FOR OVERACTIVE BLADDER TREATMENT PRODUCTS AMONG END USERS
  • 5.16 PIPELINE ANALYSIS
    • FIGURE 24 PIPELINE ANALYSIS: PHASES OF DRUGS IN CLINICAL TRIALS

6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 9 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 10 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 6.2 MIRABEGRON
    • 6.2.1 FEWER SIDE EFFECTS COMPARED WITH ANTICHOLINERGICS ARE LIKELY TO PROPEL THE GROWTH OF THIS MARKET SEGMENT
    • TABLE 11 OVERACTIVE BLADDER TREATMENT MARKET FOR MIRABEGRON, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 ANTICHOLINERGICS
    • TABLE 12 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 13 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • 6.3.1 SOLIFENACIN
      • 6.3.1.1 Solifenacin is more effective than other anticholinergics in reducing the frequency of incontinence-a key factor driving market growth
    • TABLE 14 OVERACTIVE BLADDER TREATMENT MARKET FOR SOLIFENACIN, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.2 OXYBUTYNIN
      • 6.3.2.1 Oxybutynin is the most widely prescribed anticholinergic drug in the OAB market
    • TABLE 15 OVERACTIVE BLADDER TREATMENT MARKET FOR OXYBUTYNIN, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.3 FESOTERODINE
      • 6.3.3.1 Fesoterodine exhibits antimuscarinic effects on the muscarinic acetylcholine receptors in the detrusor muscle, leading to a decrease in bladder contractions
    • TABLE 16 OVERACTIVE BLADDER TREATMENT MARKET FOR FESOTERODINE, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.4 DARIFENACIN
      • 6.3.4.1 Cost of darifenacin is higher than other anticholinergics, which is likely to restrain market growth to a certain extent
    • TABLE 17 OVERACTIVE BLADDER TREATMENT MARKET FOR DARIFENACIN, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.5 TOLTERODINE
      • 6.3.5.1 Tolterodine is the third-most-prescribed drug for OAB as it has fewer side effects and offers long-term clinical efficacy
    • TABLE 18 OVERACTIVE BLADDER TREATMENT MARKET FOR TOLTERODINE, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.6 TROSPIUM
      • 6.3.6.1 Trospium is associated with a lower incidence of dry mouth, as a result of which its discontinuation rate is relatively low
    • TABLE 19 OVERACTIVE BLADDER TREATMENT MARKET FOR TROSPIUM, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.7 OTHER ANTICHOLINERGICS
    • TABLE 20 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER ANTICHOLINERGICS, BY REGION, 2020-2027 (USD MILLION)
  • 6.4 BOTOX
    • 6.4.1 HIGHER EFFICACY OF BOTOX THAN ANTICHOLINERGICS MAKES IT A POPULAR TREATMENT ALTERNATIVE
    • TABLE 21 OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION, 2020-2027 (USD MILLION)
  • 6.5 NEUROMODULATION
    • 6.5.1 INCREASING ADOPTION OF NEUROMODULATION FOR OVERACTIVE BLADDER TREATMENT TO DRIVE GROWTH IN THIS MARKET SEGMENT
    • TABLE 22 OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROMODULATION, BY REGION, 2020-2027 (USD MILLION)
  • 6.6 OTHER TREATMENTS
    • TABLE 23 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER TREATMENTS, BY REGION, 2020-2027 (USD MILLION)

7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE

  • 7.1 INTRODUCTION
    • TABLE 24 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
  • 7.2 IDIOPATHIC OVERACTIVE BLADDER SYNDROME
    • 7.2.1 AVAILABILITY OF REIMBURSEMENTS FOR DRUGS USED TO TREAT IDIOPATHIC OAB TO FUEL GROWTH IN THIS MARKET
    • TABLE 25 IDIOPATHIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 7.3 NEUROGENIC OVERACTIVE BLADDER SYNDROME
    • TABLE 26 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 27 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 7.3.1 PARKINSON'S DISEASE
      • 7.3.1.1 Increased use of anticholinergics and beta-adrenergic agonists for the treatment of Parkinson's disease to drive market growth
    • TABLE 28 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR PARKINSON'S DISEASE, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.2 STROKES
      • 7.3.2.1 Rising prevalence of strokes to increase the incidence of OAB and fuel the demand for OAB treatment
    • TABLE 29 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR STROKES, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.3 MULTIPLE SCLEROSIS
      • 7.3.3.1 Favorable reimbursement policies to support the growth of the OAB treatment market for MS
    • TABLE 30 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.4 SPINAL CORD INJURIES
      • 7.3.4.1 High prevalence of bladder overactivity in SCI contributes to the growth of the neurogenic bladder overactivity treatment market
    • TABLE 31 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR SPINAL CORD INJURIES, BY REGION, 2020-2027 (USD MILLION)
    • 7.3.5 OTHER DISORDERS
    • TABLE 32 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER DISORDERS, BY REGION, 2020-2027 (USD MILLION)

8 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION

  • 8.1 INTRODUCTION
    • TABLE 33 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.2 NORTH AMERICA
    • FIGURE 25 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
    • TABLE 34 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 35 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 36 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 37 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 38 NORTH AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.2.1 US
      • 8.2.1.1 Favorable reimbursement policies make the US the largest market for bladder overactivity treatment
    • TABLE 39 US: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 40 US: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 41 US: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 42 US: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.2.2 CANADA
      • 8.2.2.1 Increased use of and demand for BOTOX to treat overactive bladder to drive market growth in Canada
    • TABLE 43 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 44 CANADA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 45 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 46 CANADA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.3 EUROPE
    • TABLE 47 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 48 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 49 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 50 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 51 EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.1 GERMANY
      • 8.3.1.1 Aging population and a high prevalence of OAB, especially in women, are expected to increase target patient groups in Germany
    • TABLE 52 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 53 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 54 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 55 GERMANY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.2 UK
      • 8.3.2.1 Initiatives and awareness campaigns in the UK to drive growth in the OAB market
    • TABLE 56 ANNUAL COST OF OVERACTIVE BLADDER TREATMENT IN THE UK
    • TABLE 57 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 58 UK: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 59 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 60 UK: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.3 FRANCE
      • 8.3.3.1 Low reimbursement rate in France compared to other countries may limit market growth to a certain extent
    • TABLE 61 REIMBURSEMENT RATES FOR OVERACTIVE BLADDER TREATMENT IN FRANCE
    • TABLE 62 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 63 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 64 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 65 FRANCE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.4 ITALY
      • 8.3.4.1 Italian pharmaceutical industry is expected to offer lucrative growth opportunities to OAB drug manufacturers
    • TABLE 66 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 67 ITALY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 68 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 69 ITALY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.5 SPAIN
      • 8.3.5.1 Changing demographics and high OAB prevalence in Spain offer significant growth opportunities for the bladder overactivity treatment market
    • TABLE 70 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 71 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 72 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 73 SPAIN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.3.6 REST OF EUROPE
    • TABLE 74 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 75 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 76 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 77 REST OF EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • FIGURE 26 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT
    • TABLE 78 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 79 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.4.1 JAPAN
      • 8.4.1.1 Advancements in treatment options to fuel growth in the market in Japan
    • TABLE 83 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 84 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 85 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 86 JAPAN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.4.2 CHINA
      • 8.4.2.1 Growing adoption of BOTOX for OAB treatment makes China a lucrative market
    • TABLE 87 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 88 CHINA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 89 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 90 CHINA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.4.3 INDIA
      • 8.4.3.1 India is the world's largest producer of generic drugs- a key factor driving market growth
    • TABLE 91 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 92 INDIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 93 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 94 INDIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.4.4 AUSTRALIA
      • 8.4.4.1 Growing aging population is likely to increase the number of patients suffering from OAB in Australia-a major factor supporting the growth of this market
    • TABLE 95 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 96 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 97 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 98 AUSTRALIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.4.5 REST OF ASIA PACIFIC
    • TABLE 99 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 100 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 101 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 102 REST OF ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.5 LATIN AMERICA
    • TABLE 103 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 104 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 105 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 106 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 107 LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.5.1 BRAZIL
      • 8.5.1.1 Increased use of overactive bladder drugs in the country to drive growth in the market
    • FIGURE 27 DISTRIBUTION OF POPULATION IN BRAZIL (ABOVE-60 AGE GROUP), 2004-2050
    • TABLE 108 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 109 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 110 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 111 BRAZIL: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.5.2 MEXICO
      • 8.5.2.1 Rising prevalence of OAB to drive growth in the market in Mexico
    • TABLE 112 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 113 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 114 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 115 MEXICO: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 8.5.3 REST OF LATIN AMERICA
    • TABLE 116 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 117 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 118 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 119 REST OF LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 8.6 MIDDLE EAST & AFRICA
    • 8.6.1 RISING AWARENESS OF OAB IS LIKELY TO DRIVE THE GROWTH OF THE MARKET IN THE MIDDLE EAST & AFRICA
    • TABLE 120 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 121 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 122 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 123 MIDDLE EAST & AFRICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 INTRODUCTION
  • 9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • FIGURE 28 OVERACTIVE BLADDER TREATMENT MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 9.3 MARKET SHARE ANALYSIS
    • FIGURE 29 OVERACTIVE BLADDER TREATMENT MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021)
    • TABLE 124 OVERACTIVE BLADDER TREATMENT MARKET: DEGREE OF COMPETITION
  • 9.4 REVENUE ANALYSIS
    • FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES (2019-2021)
  • 9.5 COMPANY EVALUATION QUADRANT
    • 9.5.1 STARS
    • 9.5.2 EMERGING LEADERS
    • 9.5.3 PERVASIVE PLAYERS
    • 9.5.4 PARTICIPANTS
    • FIGURE 31 OVERACTIVE BLADDER TREATMENT MARKET: COMPANY EVALUATION MATRIX, 2021
  • 9.6 COMPETITIVE BENCHMARKING OF TOP 20 PLAYERS
    • 9.6.1 COMPANY FOOTPRINT (20 COMPANIES)
    • TABLE 125 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
    • 9.6.2 COMPANY PRODUCT FOOTPRINT (20 COMPANIES)
    • TABLE 126 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
    • 9.6.3 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
    • TABLE 127 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE OVERACTIVE BLADDER TREATMENT MARKET
  • 9.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • 9.7.1 PROGRESSIVE COMPANIES
    • 9.7.2 STARTING BLOCKS
    • 9.7.3 RESPONSIVE COMPANIES
    • 9.7.4 DYNAMIC COMPANIES
    • FIGURE 32 OVERACTIVE BLADDER TREATMENT MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
    • 9.7.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
    • TABLE 128 OVERACTIVE BLADDER TREATMENT MARKET: DETAILED LIST OF KEY START-UPS/SMES
    • TABLE 129 OVERACTIVE BLADDER TREATMENT MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
  • 9.8 COMPETITIVE SCENARIO AND TRENDS
    • 9.8.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 130 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019-MAY 2022
    • 9.8.2 DEALS
    • TABLE 131 DEALS, JANUARY 2019-MAY 2022

10 COMPANY PROFILES

  • 10.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 10.1.1 ASTELLAS PHARMA INC.
    • TABLE 132 ASTELLAS PHARMA INC.: BUSINESS OVERVIEW
    • FIGURE 33 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2021)
    • 10.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 133 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
    • FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
    • 10.1.3 PFIZER INC.
    • TABLE 134 PFIZER INC.: BUSINESS OVERVIEW
    • FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2021)
    • 10.1.4 ABBVIE INC.
    • TABLE 135 ABBVIE INC.: BUSINESS OVERVIEW
    • FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2021)
    • 10.1.5 VIATRIS INC.
    • TABLE 136 VIATRIS INC.: BUSINESS OVERVIEW
    • FIGURE 37 VIATRIS INC.: COMPANY SNAPSHOT (2021)
    • 10.1.6 HISAMITSU PHARMACEUTICAL CO., INC.
    • TABLE 137 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW
    • FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2020)
    • 10.1.7 JOHNSON & JOHNSON SERVICES, INC.
    • TABLE 138 JOHNSON & JOHNSON SERVICES, INC.: BUSINESS OVERVIEW
    • FIGURE 39 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2021)
    • 10.1.8 ENDO PHARMACEUTICALS INC.
    • TABLE 139 ENDO PHARMACEUTICALS INC.: BUSINESS OVERVIEW
    • FIGURE 40 ENDO PHARMACEUTICALS INC.: COMPANY SNAPSHOT
    • 10.1.9 LUPIN
    • TABLE 140 LUPIN: BUSINESS OVERVIEW
    • FIGURE 41 LUPIN: COMPANY SNAPSHOT (2021)
    • 10.1.10 AMNEAL PHARMACEUTICALS LLC
    • TABLE 141 AMNEAL PHARMACEUTICALS LLC: BUSINESS OVERVIEW
    • FIGURE 42 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2021)
    • 10.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 142 SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
    • FIGURE 43 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
    • 10.1.12 GLENMARK
    • TABLE 143 GLENMARK: BUSINESS OVERVIEW
    • FIGURE 44 GLENMARK: COMPANY SNAPSHOT (2021)
    • 10.1.13 MACLEODS PHARMACEUTICALS LTD.
    • TABLE 144 MACLEODS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
    • FIGURE 45 MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)
    • 10.1.14 MEDTRONIC
    • TABLE 145 MEDTRONIC: BUSINESS OVERVIEW
    • FIGURE 46 MEDTRONIC: COMPANY SNAPSHOT (2021)
    • 10.1.15 AJANTA PHARMA
    • TABLE 146 AJANTA PHARMA: BUSINESS OVERVIEW
    • FIGURE 47 AJANTA PHARMA: COMPANY SNAPSHOT (2021)
    • 10.1.16 GRANULES INDIA LIMITED
    • TABLE 147 GRANULES INDIA LIMITED: BUSINESS OVERVIEW
    • FIGURE 48 GRANULES INDIA LIMITED: COMPANY SNAPSHOT (2021)
  • 10.2 OTHER PLAYERS
    • 10.2.1 UROVANT SCIENCES
    • TABLE 148 UROVANT SCIENCES: BUSINESS OVERVIEW
    • 10.2.2 APOTEX INC.
    • TABLE 149 APOTEX INC.: BUSINESS OVERVIEW
    • 10.2.3 LABORIE
    • TABLE 150 LABORIE: BUSINESS OVERVIEW
    • 10.2.4 INTAS PHARMACEUTICALS LTD.
    • TABLE 151 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
    • 10.2.5 BAYER AG
    • TABLE 152 BAYER AG: BUSINESS OVERVIEW
    • 10.2.6 MEDYTOX
    • TABLE 153 MEDYTOX: BUSINESS OVERVIEW
    • 10.2.7 ALTHERX PHARMACEUTICALS
    • TABLE 154 ALTHERX PHARMACEUTICALS: BUSINESS OVERVIEW
    • 10.2.8 TAIHO PHARMACEUTICAL CO., LTD.
    • TABLE 155 TAIHO PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW
    • 10.2.9 HUGEL, INC.
    • TABLE 156 HUGEL, INC.: BUSINESS OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 AVAILABLE CUSTOMIZATIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS